Moreover, a study on U87MG and U251 GBM cell lines demonstrated the crucial role of NEDD4 in controlling the redox imbalance in temozolomide (TMZ)-resistant GBM cells by PTEN degradation and activation of the Akt/NRF2/HO-1 signaling pathway [143]. The gene discussed is NEDD4; the disease is glioblastoma.